Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.

The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.

Pharma’s R&D engine has been firing on all cylinders in the past year – pipeline growth in 2021 stood at nearly twice that for the previous year, pushing the number of products under active development over 20,000 for the first time.

While the Omicron variant does not bode well for 2022, vaccine boosters and oral antivirals are the products from the pharmaceutical sector that should keep on giving. Even if partisan analysts choose to forget them.